Lexicon Pharma (LXRX) Tops Q4 EPS by 13c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.32 --0%
Revenue Growth %: -86.1%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
CRMT, PKE, More
Revenue Growth %: -86.1%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.16), $0.13 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $13.33 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Solstice acquiring Element Solutions in $14.5B cash and stock deal
- Solstice to acquire Element Solutions in $14.5B deal
- Prestige Consumer Healthcare closes LaCorium deal, prices $400M notes
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
